|Bid||3.0600 x 1400|
|Ask||0.0000 x 900|
|Day's Range||2.9600 - 3.1200|
|52 Week Range||2.7300 - 12.7590|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 28, 2023 - Sept 01, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.50|
Q4 2022 TRACON Pharmaceuticals Inc Earnings Call
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
It is doubtless a positive to see that the I-Mab ( NASDAQ:IMAB ) share price has gained some 83% in the last three...
To get a sense of who is truly in control of I-Mab ( NASDAQ:IMAB ), it is important to understand the ownership...
I-Mab ( NASDAQ:IMAB ) First Half 2022 Results Key Financial Results Revenue: CN¥51.9m (up 192% from 1H 2021). Net loss...
Today is shaping up negative for I-Mab ( NASDAQ:IMAB ) shareholders, with the analysts delivering a substantial...
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.